DDInter1961 DDInter899
A dideoxynucleoside compound in which the 3&#39;-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluridine
Zidovudine {u} (Compound) resembles {v} (Compound) Idoxuridine
Zidovudine {u} (Compound) resembles {v} (Compound) Telbivudine
Zidovudine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Zidovudine {u} (Compound) binds {v} (Gene) UGT2B7
Zidovudine {u} (Compound) upregulates {v} (Gene) THAP11
Zidovudine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Reverse Transcriptase Inhibitors
Zidovudine {u} (Compound) downregulates {v} (Gene) MRPS16
Zidovudine {u} (Compound) causes {v} (Side Effect) Tremor
Zidovudine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine
Zidovudine (Compound) resembles Idoxuridine (Compound)
Zidovudine (Compound) resembles Telbivudine (Compound)
Zidovudine (Compound) treats acquired immunodeficiency syndrome (Disease)
Zidovudine (Compound) binds UGT2B7 (Gene)
Zidovudine (Compound) upregulates THAP11 (Gene)
Zidovudine (Compound) is included by Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Zidovudine (Compound) downregulates MRPS16 (Gene)
Zidovudine (Compound) causes Tremor (Side Effect)
Zidovudine may cause a minor interaction that can limit clinical effects when taken with Cimetidine